Papp, Z., Agostoni, P., Alvarez, J., Bettex, D., Bouchez, S., Brito, D., Cerny, V., Comin-Colet, J., Crespo-Leiro, M., Delgado, J.,
Édes, I., Eremenko, A., Farmakis, D., Fedele, F., Fonseca, C., Fruhwald, S., Girardis, M., Guarracino, F., Harjola, V., Heringlake, M., Herpain, A., Heunks, L., Husebye, T., Ivancan, V., Karason, K., Kaul, S., Kivikko, M., Kubica, J., Masip, J., Matskeplishvili, S., Mebazaa, A., Nieminen, M., Oliva, F., Papp, G., Parissis, J., Parkhomenko, A., Põder, P., Pölzl, G., Reinecke, A., Ricksten, S., Riha, H., Rudiger, A., Sarapohja, T., Schwinger, R., Toller, W., Tritapepe, L., Tschöpe, C., Wikström, G., von Lewinski, D., Vrtovec, B., Pollesello, P.:
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
J. Cardiovasc. Pharmacol. 76 (1), 4-22, 2020.
Folyóirat-mutatók:
Q2 Cardiology and Cardiovascular Medicine
Q2 Pharmacology